1. Page numbers, where given, refer to the draft manuscript (which may differ from the published version).
2. The copyright in this report is owned by the publisher, to whom any requests for copies should be addressed.
3. This report is one of three modules; all modules are also available as a single volume, priced at £5,000.

                                 TABLE OF CONTENTS
                                                                         Page
     
     About the authors                                                      v
     Table of contents                                                    vii
     List of tables                                                      xvii
     
                 EMERGING TRENDS SHAPING THE LIFESTYLE DRUGS MARKET
     
     1 Patient-initiated-prescribing (PIP):
       implications for the OTC market                                      1
     
     2 Prospects for Rx-to-OTC switches of lifestyle drugs                  1
         2.1 The Rx-to-OTC movement                                         1
         2.2 The likely role of consumers                                   2
         2.3 The likely role of economic factors                            4
         2.4 Possible candidates for Rx-to-OTC switches                     4
     
     3 The advent of direct-to-customer (DTC) advertising                   6
         3.1 The rapidly growing US DTC advertising market                  6
         3.2 The prospects for DTC advertising in Europe                    6
     
     4 DTC advertising in the Internet healthcare market                    7
     
     5 The growth of online pharmacies                                      8
         5.1 Five categories of the online pharmacy market                  8
         5.2 Limitations of traditional distribution channels               9
         5.3 Advantages of online pharmacies                               10
         5.4 Challenges and risks facing online pharmacies                 11
     
              NEW OPPORTUNITIES IN THE TREATMENT OF SEXUAL DYSFUNCTION
     
     Sexual Dysfunction: Executive Summary                                 13
     
     Chapter 1. Sexual Dysfunction: Market & Technology Overview           15
         1.1 The spectre of sexual dysfunction                             15
         1.2 The impact of Viagra on the market                            15
         1.3 Male Erectile Dysfunction (MED)                               16
             1.3.1 Definition of MED                                       16
             1.3.2 Incidence of MED                                        17
             1.3.3 Causes of MED                                           17
             1.3.4 Diagnosis and treatment of MED                          19
         1.4 Testosterone deficiency                                       20
         1.5 Premature ejaculation                                         20
         1.6 Female sexual dysfunction (FSD)                               21
             1.6.1 Definition of FSD                                       21
             1.6.2 Incidence of FSD                                        22
         1.6.3 Causes of FSD                                               22
         1.6.4 Diagnosis and treatment of FSD                              23
     
     Chapter 2. Devices for Treatment of MED                               24
         2.1 Vacuum devices on the market                                  24
         2.2 Penile rings and bands on the market                          25
         2.3 Penile implant surgery                                        25
         2.4 Stimulation devices in development                            25
     
     Chapter 3. Pharmaceutical Products for Treatment of MED               26
         3.1 Agents applicable to treatment of MED                         26
             3.1.1 Prostaglandins                                          26
             3.1.2 Phosphodiesterase (PDE) inhibitors                      26
             3.1.3 Alpha-blockers                                          26
             3.1.4 Dopamine agonists                                       27
             3.1.5 Nitric oxide (NO) donors                                27
             3.1.6 Androgens                                               27
             3.1.7 Miscellaneous agents                                    27
         3.2 Products on the market                                        28
             3.2.1 Penile injection products                               28
             3.2.2 Transurethral products                                  28
             3.2.3 Oral products                                           29
             3.2.4 Sublingual products                                     30
         3.3 Products in development                                       30
             3.3.1 Penile injection products                               30
             3.3.2 Pain-free penile injection products                     30
             3.3.3 Non-penile injection products                           30
             3.3.4 Needle-free injection products                          30
             3.3.5 Transurethral products                                  31
             3.3.6 Oral products                                           31
             3.3.7 Sublingual and intranasal products                      32
             3.3.8 Topical products                                        32
             3.3.9 Transdermal products                                    33
     
     Chapter 4. Products for Treatment of Testosterone Deficiency          35
         4.1 Products on the market                                        35
         4.2 Products in development                                       35
     
     Chapter 5. Products for Treatment of FSD                              36
         5.1 Products on the market                                        36
         5.2 Products in development                                       36
     
     Chapter 6. Profiles of Selected Companies in the
                Sexual Dysfunction Market                                  37
         Antares Pharma (formerly Medi-Ject)                               37
         Bentley Pharmaceuticals Inc                                       38
         Bio-Technology General Corp                                       39
         Biosonics Inc                                                     40
         Cortex Pharmaceuticals Inc                                        41
         Harvard Scientific Corp                                           42
         ICOS Corporation                                                  44
         Ligand Pharmaceuticals                                            45
         Macrochem Corporation                                             46
         Nastech Pharmaceutical Company Inc                                47
         NexMed Inc                                                        48
         Nitromed Inc                                                      49
         Palatin Technologies Inc                                          50
         Pfizer Inc                                                        51
         Senetek pIc                                                       53
         TAP Pharmaceutical Products Inc                                   55
         UroMetrics Inc                                                    56
         Vivus Inc                                                         57
         Watson Laboratories Inc (formerly TheraTech)                      59
         Zonagen Inc                                                       61
     
         Glossary                                                          65
     
     Chapter 7. Sexual Dysfunction Market:
                Quantitative Analysis & Forecasts                          66
         7.1 World pharmaceutical market by region in 2000                 66
             7.1.1 Geographical predictions                                66
         7.2 Sexual dysfunction market analysis by category                66
             7.2.1 Oral                                                    68
             7.2.2 Androgens                                               69
             7.2.3 Topical                                                 69
             7.2.4 Female sexual dysfunction                               69
     
     Chapter 8. Sexual Dysfunction: Trends & Opportunities                 71
         8.1 Viagra: euphoria and reality                                  71
         8.2 Viagra: new opportunities all round                           71
             8.2.1 Nutritional supplements and lubricants                  72
             8.2.2 Condoms                                                 72
         8.3 Non-invasive treatments of MED: in great demand               72
         8.4 Invasive treatments of MED: out of favour                     73
         8.5 Testosterone replacement: increasingly in demand              73
         8.6 FSD: little-understood but a vast potential market            74
     
                                   LIST OF TABLES
     
     Table 1 Drugs and devices for the treatment MED,
             by mode of delivery                                           62
     Table 2 Replacement therapies for testosterone                        64
     Table 3 Drugs and devices for the treatment of FSD,
             by mode of delivery                                           64
     Table 4 World pharmaceutical market by region 2000                    67
     Table 5 Selected world market for sexual dysfunction
             drug treatments, 2000 and 2005                                70
     Table 6 Sexual dysfunction market segment predictions 2005            70